Jonathan Young - 10 Mar 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
14 Mar 2023, 16:19:46 UTC
Prior SEC filing
05 Jan 2023
Next SEC filing
15 Jun 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jonathan Young

Key filing fact

Jonathan Young filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 14 Mar 2023.

Key facts

  • This page summarizes Jonathan Young's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Mar 2023, 16:19.

Change

  • Previous filing in this sequence was filed on 05 Jan 2023.
  • Current net transaction value: -$27,560.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AKRO transaction

Common Stock

Tax liability

Transaction value
$27,560
Shares
-634
Change %
-0.34%
Price
$43.47
Shares after
184,277
Date
10 Mar 2023
Ownership
Direct
Footnotes
F1
AKRO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
20,000
Date
10 Mar 2023
Ownership
By EA Irrevocable Trust
Footnotes
F2
AKRO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
20,000
Date
10 Mar 2023
Ownership
By CM Irrevocable Trust
Footnotes
F2
AKRO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
20,000
Date
10 Mar 2023
Ownership
By JL Irrevocable Trust
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.

Footnote F2

These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .